|Back to main|
Walgreen Co (WAG): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report
Walgreens reported a mixed third quarter fiscal 2014 with adjusted earnings remaining below the Zacks Consensus Estimate while revenues marginally exceeded the mark. During the quarter, Walgreens recorded improved revenues on back of strong prescription sales performance. Sales growth was also driven by the company's gaining share in the pharmacy market. Furthermore, Walgreens has experienced return of some Express Scripts customers. The higher first-year synergy from the Alliance Boots deal was another upside. We are also upbeat about the long-term three-pronged-deal with AmerisourceBergen. However, deteriorating margin and difficult macroeconomic conditions remain as looming concerns. The competitive landscape also remains tough. Accordingly, we remain Neutral on Walgreens.
Headquartered in Deerfield, IL, Walgreen Co. (WAG), popularly known as Walgreens, is the largest national retail pharmacy chain in terms of revenue and profitability. As of May 31, 2014, Walgreens operated 8,683 locations in all 50 states of the U.S., the District of Columbia, Puerto Rico and Guam and the U.S. Virgin Islands, including 8,217 drugstores (120 more compared with the year-ago period). The company also operates infusion and respiratory service facilities, worksite health and wellness centers, specialty pharmacies and mail service facilities. Its Take Care Health Systems subsidiary manages more than 700 in-store convenient care clinics and worksite health and wellness centers. Walgreens' e-commerce business includes Walgreens.com, drugstore.com, Beauty.com, SkinStore.com and VisionDirect.com.
The drugstores, apart from selling prescription drugs, also sell over-the-counter (OTC) medications, general merchandise, cosmetics, toiletries, household items and food and beverages. Due to carefully selected locations, the stores offer easy accessibility with many of them remaining open for 24 hours. The company ensures robust traffic in the stores by offering a broad selection of consumable merchandise backed by strong advertising programs.
In Aug 2012, Walgreens had entered into a strategic partnership with a global international pharmacy-led health and beauty group Alliance Boots GmbH, in which it acquired a 45% stake for $6.7 billion. The company also has the option to obtain 100% ownership over the next three years for an approximate value of $9.5 billion in cash and stock.
In Oct 2013, Walgreens and Alliance Boot arrived at a long-term and strategic relationship with AmerisourceBergen. As per the agreement, Walgreens and AmerisourceBergen have successfully begun implementing their 10-year agreement for pharmaceutical distribution from early Sep 2013. AmerisourceBergen has also teamed up with Alliance Boots and Walgreens under a three-pronged agreement that underlines a strategic collaboration, equity alignment and distribution agreement.
Generic: The Current Scenario The ongoing introduction of prescription drugs in the generic market is changing the mode of patient care which affects the business of drug retailers like Walgreens. This is because the retail price of generic drugs is lower compared to that of brand name drugs. Moreover, over the past year, inflation in generic drug cost has adversely affected Walgreens' margin. While the introduction of generics has notably dragged sales over the last few quarters, the company expects the gross margin to improve in the ongoing fourth quarter. Management expects the rate of generic drug introduction to rise in the fourth quarter, to the point that it shall no longer have any negative impact on Walgreens' margin.
Walgreen Co (WAG): Read the Full Research Report
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
WALGREEN CO (WAG): Free Stock Analysis Report
To read this article on Zacks.com click here.